The earnings estimates are way off. Average analyst estimates were that mnta would lose 5 cent per share this quarter, high estimate that mnta would earn 5 cent per share. Based on our discussions here, I estimate 66 cents - 1.20 cents in earnings this quarter.
Just to be clear: the brusque admonition to the sell-side analysts in #msg-55775261 was motivated not by the analysts’ sales projection for Lovenox, but rather by their failure to investigate the story behind Teva’s Lovenox ANDA.
Market Data 
Markets 
AI
